A national study of a telephone support service for patients receiving office-based buprenorphine medication-assisted treatment: Study feasibility and sample description

Journal of Substance Abuse Treatment

Volumn 39, Issue 4, 2010, Pages 307-317

  Ruetsch, Charles ^a   Cacciola, John ^b   Tkacz, Joseph ^a  

^a Health Analytics LLC   (United States)

^b TREATMENT RESEARCH INSTITUTE   (United States)

Author keywords

Buprenorphine; Opioid dependence; Telephone support

Indexed keywords

BUPRENORPHINE;

ADULT; ARTICLE; FEASIBILITY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTIVATION; OPIATE ADDICTION; PATIENT EDUCATION; PHYSICIAN; PRIORITY JOURNAL; SUBSTITUTION THERAPY; TELEMEDICINE;

ADULT; AMBULATORY CARE; BUPRENORPHINE; DATA COLLECTION; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT SELECTION; RESEARCH DESIGN; TELEPHONE; UNITED STATES; YOUNG ADULT;

EID: 78049246987     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2010.07.003     Document Type: Article

References (39)

1. Amato L., Davoli M., Perucci C.A., Ferri M., Faggiano F., Mattick R.P. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. Journal of Substance Abuse Treatment 2005, 28:321-329.
2. Barnett P.G. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction 2009, 104:982-992.
3. Bell J., Burrell T., Indig D., Gilmour S. Cycling in and out of treatment; Participation in methadone treatment in NSW, 1990-2002. Drug & Alcohol Dependence 2006, 81:55-61.
4. Braithwaite D., Emery J., de Lusignan S., Sutton S. Using the Internet to conduct surveys of health professionals: A valid alternative?. Family Practice 2003, 20:545-551.
5. Cacciola J.S., Alterman A.I., Lynch K.G., Martin J.M., Beauchamp M.L., McLellan A.T. Initial reliability and validity studies of the Revised Treatment Services Review (TSR-6). Drug & Alcohol Dependence 2008, 92:37-47.
6. Cacciola J.S., Camilleri A.C., Carise D., et al. Extending residential care through telephone counseling: Initial results from the Betty Ford Center focused continuing care protocol. Addictive Behaviors 2008, 33:1208-1216.
7. Carise D., McLellan A.T., Gifford L.S., Kleber H.D. Developing a national addiction treatment information system. An introduction to the Drug Evaluation Network System. Journal of Substance Abuse Treatment 1999, 17:67-77.
8. Carrieri M.P., Amass L., Lucas G.M., Vlahov D., Wodak A., Woody G.E. Buprenorphine use: The international experience. Clinical Infectious Diseases 2006, 43(Suppl 4):S197-S215.
9. Center for Substance Abuse Treatment Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939 2004, Substance Abuse and Mental Health Services Administration, Rockville, MD.
10. Connock M., Juarez-Garcia A., Jowett S., Frew E., Liu Z., Taylor R.J., et al. Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health Technology Assessment (Winchester, England) 2007, 11:1-171.
11. Cramer J., Rosenheck R., Kirk G., et al. Medication compliance feedback and monitoring in a clinical trial: Predictors and outcomes. Value Health 2003, 6:566-572.
12. Darke S. Self-report among injecting drug users: A review. Drug and Alcohol Dependence 1998, 51:253-263.
13. Dolor R.J., Yancy W.S., Owen W.F., et al. Hypertension improvement project (HIP): Study protocol and implementation challenges. Trials [Electronic Resource] 2009, 10:13.
14. East L., Jackson D., O'Brien L., Peters K. The benefits of computer-mediated communication in nursing research. Contemporary Nurse 2008, 30:83-88.
15. Eisen A., Kushner H., McLeod M., Queen E., Gordon J., Ford J.L. An integrated approach to addressing addiction and depression in college students. Journal of American College Health 2009, 57:455-456.
16. Elder J.P., Ayala G.X., Harris S. Theories and intervention approaches to health-behavior change in primary care. American Journal of Preventive Medicine 1999, 17:275-284.
17. Fiellin D.A., et al. Long-term treatment with buprenorphine/naloxone in primary care: Results at 2-5 years. Am J Addict 2008, 17:116-120.
18. Geurts M., Blowers L. Global subject recruitment. Applied Clinical Trials 2009, 18:91-93. Retrieved from. http://search.ebscohost.com.proxy-hs.researchport.umd.edu/login.aspx?direct=true&db=aph&AN=37179067&site=ehost-live.
19. Hubbard R.L., Leimberger J.D., et al. Telephone Enhancement of Long-term Engagement (TELE) in continuing care for substance abuse treatment: A NIDA clinical trials network (CTN) study. American Journal on Addictions 2007, 16:495-502.
20. Improving outcomes for opioid-addicted youth Harvard Mental Health Letter 2009, 25:7.
21. Kastelic A., Pont J., Heino S. Opioid Substitution Treatment in Custodial Settings 2008, World Health Organization; United Nations Office on Drugs and Crime.
22. Katz N., Fernandez K., Chang A., Benoit C., Butler S.F. Internet-based survey of nonmedical prescription opioid use in the United States. Clinical Journal of Pain 2008, 24:528-535.
23. Kaur A.D., McQueen A., Jan S. Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use. Journal of Managed Care Pharmacy 2008, 14:186-194.
24. Magura S, et al. Outcomes of buprenorphine maintenance in office-based practice. Journal of Addictive Diseases 2007, 26:13-23.
25. Magura S., Lee J.D., Hershberger J., Joseph H., Marsch L., Shropshire C., et al. Buprenorphine and methadone maintenance in jail and post-release: A randomized clinical trial. Drug & Alcohol Dependence 2009, 99:222-230.
26. McKay J.R., Lynch K.G., Shepard D.S., Pettinati H.M. The effectiveness of telephone-based continuing care for alcohol and cocaine dependence: 24-Month outcomes. Archives of General Psychiatry 2005, 62:199-207.
27. McLellan A.T., Arndt I.O., et al. The effects of psychosocial services in substance abuse treatment. JAMA 1993, 269:1953-1959.
28. McLellan A.T., Cacciola J.C., et al. The Addiction Severity Index at 25: Origins, contributions and transitions. American Journal on Addictions 2006, 15:113-124.
29. McLellan A.T., Hagan T.A., Levine M., et al. Supplemental social services improve outcomes in public addiction treatment. Addiction 1998, 93:1489-1499.
30. McLellan A.T., Kushner H., Metzger D., et al. The fifth edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 1992, 9:199-213.
31. Morin K., Rakatansky H., Riddick F.A., Morse L.J., O'Bannon J.M., Goldrich M.S., et al. Managing conflicts of interest in the conduct of clinical trials. JAMA 2002, 287:78-84.
32. Netherland J., Botsko M., Egan J.E., Saxon A.J., Cunningham C.O., Finkelstein R., et al. Factors affecting willingness to provide buprenorphine treatment. Journal of Substance Abuse Treatment 2009, 36:244-251.
33. Ridge G., Gossop M., Lintzeris N., Witton J., Strang J. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. Journal of Substance Abuse Treatment 2009, 37:95-100.
34. Schottenfeld R.S., Chawarski M.C., Mazlan M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: A randomized, double-blind, placebo-controlled trial. Lancet 2008, 371:2192-2200.
35. Scott C.K., Dennis M.L. Results from two randomized clinical trials evaluating the impact of quarterly recovery management checkups with adult chronic substance users. Addiction 2009, 104:959-971.
36. Shimm D.S., Spece R.G. Industry reimbursement for entering patients into clinical trials: Legal and ethical issues. Annals of Internal Medicine 1991, 115:148-151.
37. Substance Abuse and Mental Health Services Administration, Office of Applied Studies Treatment episode data set (TEDS) highlights-2007 national admission to substance abuse treatment services No. OAS Seris #S-45, HHS Publication No.(SMA) 09-4360) 2009, US Department of Health and Human Services, Rockville, MD.
38. United States. Department of Health and Human Services. - Inspections, Compliance, Enforcement, and Criminal Investigations. U.S Food and Drug Administration, 2009. Web. http://www.fda.gov/ICECI/EnforcementActions/BioresearchMonitoring/ucm133927.htm.
39. Zanis D.A., McLellan A.T., Corse S. Is the Addiction Severity Index a reliable and valid assessment instrument among clients with severe and persistent mental illness and substance abuse disorders?. Community Mental Health Journal 1997, 33:213-227.